|Bid||0.00 x 1400|
|Ask||0.00 x 1800|
|Day's range||59.82 - 60.86|
|52-week range||42.48 - 60.86|
|Beta (3Y monthly)||0.68|
|PE ratio (TTM)||17.33|
|Earnings date||22 Jan 2020 - 27 Jan 2020|
|Forward dividend & yield||1.64 (2.76%)|
|1y target est||64.70|
Studies Evaluating Liso-Cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
BRISTOL-MYERS SQUIBB ANNOUNCES LISO-CEL MET PRIMARY AND SECONDARY ENDPOINTS IN TRANSCEND NHL 001 STUDY
(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at email@example.com;Michelle Fay Cortez in Minneapolis at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
BMS and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
Zacks.com featured highlights include: Target, Medtronic Public, Arconic, Science Applications International and Bristol-Myers Squibb
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol-Myers (BMY) and Acceleron Pharma Inc.'s sBLA for Reblozyl in patients with myelodysplastic syndromes will be reviewed by the FDA's Oncologic Drugs Advisory Committee.
Roche (RHHBY) obtains FDA approval for Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic NSCLC.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Does the December share price for Bristol-Myers Squibb Company (NYSE:BMY) reflect what it's really worth? Today, we...
Bristol-Myers Squibb Company (BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA® (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors. Stem cell transplants have been shown to be an effective treatment for aggressive leukemias and other hematological malignancies, often representing the only therapeutic option for cure. “While ideally we prefer using fully matched transplants from a sibling for the treatment of hematologic cancers, only the minority of patients have such a sibling,” said study lead investigator Leslie Kean, M.D., Director of the Stem Cell Transplantation Program, Dana Farber/Boston Children’s Cancer and Blood Disorders Center.
Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for the use of Reblozyl® (luspatercept-aamt) in patients with myelodysplastic syndromes (MDS) at its meeting on December 18, 2019. Bristol-Myers Squibb is seeking approval of Reblozyl, an erythroid maturation agent representing a new class of therapy, for the treatment of adult patients with very low- to intermediate-risk MDS-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.